

Regimen Reference Order – CUTA - cemiplimab

ARIA: CUTA – [cemiplimab]

Planned Course: Every 21 days for up to 32 cycles
Indication for Use: Advanced Cutaneous Squamous Cell Carcinoma
Drug Alert: Immune Checkpoint Inhibitor
CVAD: At Provider’s Discretion

Proceed with treatment if:

- *ANC equal to or greater than 1.5 x 10⁹/L AND Platelets equal to or greater than 50 x 10⁹/L*
 - *AST/ALT equal to or less than 3 times the upper limit of normal*
 - *Total bilirubin equal to or less than 1.5 times the upper limit of normal*
 - *Creatinine clearance equal to or greater than 30 mL/minute*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA - cemiplimab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
cemiplimab	350 mg	IV in normal saline 100 mL over 30 minutes <i>Use 0.2 or 0.22 micron filter</i>

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin, glucose, serum cortisol and TSH as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Patient should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
 - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

ADDITIONAL INFORMATION

- cemiplimab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated